GBR 1342, an investigational bispecific antibody developed by Glenmark Pharmaceuticals, was granted orphan drug designation by the U.S Food and Drug Administration (FDA) for…
News
Ygalo (melflufen) combination therapy continues to demonstrate promising results, without significant side effects, in patients with relapsed or refractory multiple myeloma, updated data…
Designing CAR T-cells to specifically target GPRC5D — a protein appreciably present on the surface of myeloma cells — may be a safe and effective…
Henry Schein, a foundation devoted to promoting dental and medical health, has produced more than 27,000 comfort kits for people fighting cancer in the U.S.
The addition of Keytruda (pembrolizumab) to standard therapy — Revlimid (lenalidomide) or Pomalyst (pomalidomide) in combination with dexamethasone…
Shlomit Norman was 42 when doctors diagnosed her with multiple myeloma — an incurable bone marrow cancer that rarely strikes people under the age…
The U.S. Food and Drug Administration (FDA) has granted the designation of orphan drug to CT053, one of CARsgen Therapeutics’ lead CAR…
The European Commission (EC) has approved Empliciti (elotuzumab) in combination with Pomalyst (pomalidomide) and low-dose dexamethasone for the treatment…
GlaxoSmithKline’s investigational antibody-drug conjugate, belantamab mafodotin (GSK2857916), demonstrated a clinically meaningful overall response rate in hard-to-treat multiple myeloma patients in a Phase…
People in Japan newly diagnosed with multiple myeloma and ineligible for a stem cell transplant can now use a combination of Darzalex (daratumumab) and standard…
